Literature DB >> 14512527

Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Ju-Tao Guo1, Qing Zhu, Christoph Seeger.   

Abstract

Hepatitis C virus (HCV) is the only known positive-stranded RNA virus that causes persistent lifelong infections in humans. Accumulation of HCV RNA can be inhibited with alpha interferon (IFN-alpha) in vivo and in culture cells. We used cell-based assay systems to investigate the mechanisms responsible for the cytokine-induced inhibition of HCV replication. The results showed that IFN-alpha could suppress the accumulation of viral RNA by a noncytopathic pathway and could also induce apoptosis of virally infected cells in a concentration- and cell line-dependent fashion. Whereas the noncytopathic IFN-alpha response depended on a functional Jak-STAT signal transduction pathway, it did not appear to require double-stranded RNA-dependent pathways. Moreover, we found that functional proteasomes were required for establishment of the IFN-alpha response against HCV. Based on the results described in this study we propose a model for the mechanism by which IFN-alpha therapy suppresses HCV replication in chronic infections by both cytopathic and noncytopathic means.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512527      PMCID: PMC224980          DOI: 10.1128/jvi.77.20.10769-10779.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors.

Authors:  Tadatsugu Taniguchi; Akinori Takaoka
Journal:  Curr Opin Immunol       Date:  2002-02       Impact factor: 7.486

Review 2.  Viruses and interferons.

Authors:  G C Sen
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

Review 3.  Signal integration via PKR.

Authors:  B R Williams
Journal:  Sci STKE       Date:  2001-07-03

4.  Inhibition of hepatitis B virus replication by interferon requires proteasome activity.

Authors:  Michael D Robek; Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians.

Authors:  J L Kinzie; P H Naylor; M G Nathani; R R Peleman; M N Ehrinpreis; M Lybik; J R Turner; J J Janisse; M Massanari; M G Mutchnick
Journal:  J Viral Hepat       Date:  2001-07       Impact factor: 3.728

6.  Effect of alpha interferon on the hepatitis C virus replicon.

Authors:  J T Guo; V V Bichko; C Seeger
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons.

Authors:  K C Goh; S J Haque; B R Williams
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

8.  Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication.

Authors:  Marek Radkowski; Jeffrey Wilkinson; Marek Nowicki; Debra Adair; Hugo Vargas; Craig Ingui; Jorge Rakela; Tomasz Laskus
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 9.  How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A.

Authors:  S L Tan; M G Katze
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

10.  Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs.

Authors:  Michael Frese; Verena Schwärzle; Kerstin Barth; Nicole Krieger; Volker Lohmann; Sabine Mihm; Otto Haller; Ralf Bartenschlager
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

View more
  23 in total

1.  Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon.

Authors:  Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Masashi Mizokami; Takaji Wakita
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins.

Authors:  Wen Jun Liu; Xiang Ju Wang; Vladislav V Mokhonov; Pei-Yong Shi; Richard Randall; Alexander A Khromykh
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  West Nile virus inhibits the signal transduction pathway of alpha interferon.

Authors:  Ju-Tao Guo; Junpei Hayashi; Christoph Seeger
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.

Authors:  Vanessa Escuret; Amaury Martin; David Durantel; Romain Parent; Olivier Hantz; Christian Trépo; Thierry Menguy; Emmanuel Bottius; Jerome Dardy; Jean Maral; Jean Louis Escary; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2006-10-09       Impact factor: 5.191

5.  Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells.

Authors:  Harel Dahari; Ruy M Ribeiro; Charles M Rice; Alan S Perelson
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

6.  RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus.

Authors:  Rodney P Kincaid; Victor L Lam; Rachel P Chirayil; Glenn Randall; Christopher S Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

7.  Differential effects of mutations in NS4B on West Nile virus replication and inhibition of interferon signaling.

Authors:  Jared D Evans; Christoph Seeger
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus.

Authors:  Dong Jiang; Haitao Guo; Chunxiao Xu; Jinhong Chang; Baohua Gu; Lijuan Wang; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

9.  Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway.

Authors:  Rongjuan Pei; Xiaoyong Zhang; Song Xu; Zhongji Meng; Michael Roggendorf; Mengji Lu; Xinwen Chen
Journal:  Virol Sin       Date:  2012-09-21       Impact factor: 4.327

10.  Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.

Authors:  Leda Bassit; Jason Grier; Matthew Bennett; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.